Each experimental consent document offered some combination of the following three data release options: (1) public data release (release of genetic and clinical information into both publicly accessible (opzen access via the internet) and restricted (accessible only to approved researchers) scientific databases), (2) restricted release (release of genetic and clinical information into restricted databases only), and (3) no release (accessible only to the genomic study PI and his or her staff) (Table 1).
